APTYS Pharmaceuticals announces the creation of its new subsidiary APTYS Pharmaservices.
After more than fifteen years of activity, the company has reached a maturity level which led to the separation of its two historical activities with the creation of a subsidiary, totally and exclusively dedicated to its service activity.
Since 2002, APTYS has exercised its galenic formulation activity based on patented technologies and analytical development as a service provider but also internally with the objective of providing licenses to third parties.
Thus, in 2005, Bioalliance Pharma acquired the Loramyc®/Oravig® rights, an oral bioadhesive form of miconazole for the treatment of oropharyngeal candidiasis. In 2013, Viramal acquired the Testocream® rights, a transdermal form of testosterone, for the treatment of hypogonadism.
2017 was a significant year as APTYS obtained the pharmaceutical establishment status for its quality control activity. It signed a partnership agreement with Unither Pharaceuticals to develop an innovative product for pain treatment. Such innovation led to a co-funding venture including the Rhône-Alpes Region/FEDER/BPI.
The year 2018 saw its qualification by the World Health Organization for its quality control activity, and the entry of a new investor into the company’s capital to continue funding the pain treatment project.